This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gilead Preview: HIV Drugs Still Focus

Investor attention will once again return to the performance of Gilead Sciences' (GILD - Get Report) HIV drug franchise when the company reports first-quarter earnings Tuesday.

Lately Wall Street has focused its attention on Gilead's efforts to diversify outside of the HIV treatment market. This includes a push into cardiovascular disease with the $1 billion acquisition of CV Therapeutics (CVTX) and the release of initial phase III results from the company's experimental high blood pressure drug darusentan.

Yet it will be growth in Gilead's HIV drugs (primarily Atripla and Truvada) that is expected to fuel an 18% increase in adjusted first-quarter profits to 63 cents a share on total revenue of just over $1.5 billion, according to Thomson Reuters. In the year-ago quarter, Gilead earned 51 cents a share on revenue of $1.25 billion.

Biotech Select

Worldwide HIV sales are expected to increase about 5% to $1.26 billion in the quarter. Of that total, worldwide Atripla sales should total $507 million, up 9% sequentially and 56% year over year. Global sales of Truvada are expected to reach $571 million, up 2% sequentially and 20% year over year, according to the consensus analyst estimates.

Inventory reductions on the wholesale and retail level could weigh on Gilead's top-line performance. Inventory drawdowns hurt fourth-quarter 2008 sales to a degree. If that continued or intensified during the first quarter, Gilead would be at risk of missing consensus sales and earnings estimates.

Recently released prescription data for the first quarter has either signaled a slowdown in Gilead's HIV sales or matched consensus expectations, depending on different analyst interpretations. And Abbott Labs (ABT - Get Report) posted soft first-quarter sales of its leading HIV drug Kaletra.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ABT $46.93 -0.15%
GILD $103.07 -2.50%
AAPL $126.34 -1.80%
FB $77.72 -1.40%
GOOG $531.87 -1.60%

Markets

DOW 17,947.39 -123.01 -0.68%
S&P 500 2,089.50 -24.99 -1.18%
NASDAQ 4,941.4750 -75.4540 -1.50%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs